Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04320823 · ClinicalTrials.gov registry record · NA
IMPACT (Improving Plasma Collection) Clinical Trial
A NA study of Apheresis Related Hypotension, sponsored by Haemonetics Corporation.
- Completed
- Registry status
- NA
- Development phase
- 3,443
- Enrollment target
- 3
- Study locations
NCT04320823: Completed NA study of Apheresis Related Hypotension, sponsored by Haemonetics Corporation.
NCT04320823 is a NA study of Apheresis Related Hypotension that has completed, run by Haemonetics Corporation. The registered enrollment target is 3,443 participants, above the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (145% higher). The trial reports 3 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04320823, a NA study of Apheresis Related Hypotension, has completed, sponsored by Haemonetics Corporation.
- COMPLETED
- Registry status
- NA
- Development phase
- 3,443 participants
- Enrollment target
- 3
- Study locations
Study Summary
Prospective, multi-center, randomized, controlled clinical trial to study the safety and effectiveness of a novel plasma collection system software.
Primary Outcome
The incidence rate of at least one significant hypotensive (vasovagal/hypovolemia) adverse event according to the plasma center adverse event reporting system, based on IQPP definitions of Signs/Symptoms/Findings. Significant adverse events are defined as such events that fulfill the Signs/Symptoms/Findings of IQPP Donor Adverse Events (DAE) classifications 1.2 through 1.6 per the modified, symptoms-based approach following the plasma center adverse event reporting system. A Model Based Predic
Conditions Studied
Interventions
- DEVICE Updated Plasma Collection Feature
- DEVICE Current Plasma Collection Approach
Study Locations (3)
Kansas
- Octapharma Plasma - Wichita
North Carolina
- Octapharma Plasma - Charlotte
Washington
- Octapharma Plasma - Spokane
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3,443 participants |
| Start Date | 2020-01-06 |
| Est. Completion | 2020-04-27 |
| Phase | NA |
What the finished NCT04320823 record still lists
NCT04320823 is an interventional study that assigns participants to a tested intervention. Its 3,443 participants enrollment target places it among the larger protocols in the corpus, above the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (145% higher).
The record links to 1 condition, with Apheresis Related Hypotension appearing as the primary indexed condition, and to 2 interventions - of which Updated Plasma Collection Feature is the first listed.
NCT04320823 reports a single indexed study location in Kansas, North Carolina, Washington.
Frequently Asked Questions
What is clinical trial NCT04320823 about?
NCT04320823 is a clinical study titled "IMPACT (Improving Plasma Collection) Clinical Trial". Prospective, multi-center, randomized, controlled clinical trial to study the safety and effectiveness of a novel plasma collection system software.
What is the current status of trial NCT04320823?
This trial is currently completed. It is a NA study. The enrollment target is 3,443 participants. The study started on 2020-01-06. Estimated completion is 2020-04-27.
What conditions does trial NCT04320823 study?
This clinical trial studies the following conditions: Apheresis Related Hypotension.
What interventions are being tested in trial NCT04320823?
The interventions under investigation include: Updated Plasma Collection Feature (DEVICE), Current Plasma Collection Approach (DEVICE).
Who is sponsoring clinical trial NCT04320823?
This trial is sponsored by Haemonetics Corporation, which has 11 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04320823 being conducted?
This trial has 3 study locations across Kansas, North Carolina, Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04320823's enrollment target sits among peer trials
3,443 37th of 2000 higher than 1,964 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03474029 · 3,400 participants · Phase 2
Assessment of the Safety, Tolerability, and Effectiveness of Rifapentine Given Daily for LTBI
- NCT07142954 · 3,400 participants · Phase 3
Epidemiology and Biomarker Study in Alzheimer's Disease
- NCT00260559 · 3,500 participants
Outcomes After Esophagectomy With a Focus on Minimally Invasive Esophagectomy and Quality of Life
- NCT01612949 · 3,500 participants
Facial Analysis to Classify Difficult Intubation
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI